A combined Phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naive subjects with neovascular age related macular degeneration

Trial Profile

A combined Phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naive subjects with neovascular age related macular degeneration

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Regorafenib (Primary) ; Ranibizumab
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms DREAM
  • Sponsors Bayer
  • Most Recent Events

    • 25 Jul 2016 Status changed from completed to discontinued.
    • 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 15 Feb 2015 Planned number of patients changed from 540 to 350 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top